Clinical and Experimental Immunology
P O S T E R P R E S E N TAT I O N S
7th International Immunoglobulin Conference: Poster Presentations
K. Warnatz,* M. Ballow,† M. Stangel‡ and V. Bril§ *Centre for Chronic Immunodeficiencies, Freiburg, Germany, †University of South Florida, St Petersburg, FL, USA, ‡Department of Neurology, Hannover Medical School, Hannover, Germany, and §University of Toronto, Toronto, Canada
Correspondence: K. Warnatz. E-mail: [email protected]
Summary The pan-European survey provides useful information on the accessibility and trends of intravenous and subcutaneous immunoglobulin (IVIg/SCIg) therapy, which is used to treat primary immunodeficiency disorders (PIDs). Although immunoglobulin (Ig) therapy is the first-line treatment for PIDs, the mechanisms of action of Ig therapy may differ according to the condition it is used to treat. Moreover, intriguing presentations suggest that further investigation is required to understand more clearly both the haematological and immunoregulatory effects of therapeutic immunoglobulin. This can ultimately provide more information on optimizing Ig therapy efficacy, and establish whether individualized dosing regimens for patients will be conducive to better clinical outcomes. In addition to treating autoimmune and inflammatory conditions, there is evidence to suggest that immunoglobulins can potentially play a role in transplantation, which warrants further investigation for future use.
© 2014 British Society for Immunology, Clinical and Experimental Immunology, 178: 162
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.